


Supplementary eTable 1. Psychotropic Medications Discontinued Prior to Starting Trial


Randomization Group	Participant	Medication	Dose
IPSRT +PLACEBO	1	Trazodone	200 mg qhs
		Bupropion	300 mg daily
		Sertraline	150 mg daily
	2	Sertraline	100 mg daily
	3	Aripiprazole	5 mg daily
		Bupropion	150 mg daily
		Desvenlafaxine	100 mg daily
	4	Citalopram	20 mg daily
		Valproate	1000 mg daily
	5	Eszopiclone	1 mg qhs prn
		Temazepam	1 mg qhs prn
		Vilazodone	40 mg qhs
	6	Mixed amphetamine salts	5 mg daily
		Lithium carbonate	900 mg daily
		Trazodone	50 mg qhs prn
	7	Duloxetine	30 mg daily
8	Mixed amphetamine salts	20 mg daily	
9	Bupropion	100 mg daily	
	Alprazolam	0.25 mg daily prn	
10	Alprazolam	0.25 mg daily prn	
11	Aripiprazole	1 mg daily	
	Citalopram	20 mg daily	
IPSRT + QUETIAPINE	13	Escitalopram	10 mg daily
	14	Sertraline	50 mg daily
	15	Citalopram	30 mg daily
	16	Duloxetine	60 mg daily
	17	Sertraline	200 mg daily
	18	Zolpidem	2.5 mg qhs prn

Supplementary eFigure 1. Estimated change in Body Mass Index (BMI) values Using Mixed-Effect Models (a)



(a) ( $F=6.671$ ,  $df=67.96$ ;  $p=.012$ ) The curves represent an estimated linear model

Supplementary eFigure 2. Baseline Young Mania Rating Scale (YMRS) as Moderator of Treatment Response (a)



(a) Curves show decreased predicted probability of response to IPSRT plus quetiapine compared to IPSRT plus placebo with > 9 hypomanic symptoms (OR=0.872, 95% CI= 0.760-0.999, p=.048)